HIGH-COST MEDICATIONS IN THE SUS: COPD PATIENTS IN A VULNERABLE STATE. Editora Impacto Científico, [S. l.], p. 211–219, 2025. DOI: 10.56238/edimpacto2025.028-022. Disponível em: https://periodicos.newsciencepubl.com/editoraimpacto/article/view/8344. Acesso em: 7 feb. 2026.